Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-22.29 Insider Own6.08% Shs Outstand1.46M Perf Week-15.50%
Market Cap2.47M Forward P/E- EPS next Y-4.33 Insider Trans9.85% Shs Float1.37M Perf Month-30.74%
Income-19.85M PEG- EPS next Q-1.44 Inst Own4.14% Short Float6.90% Perf Quarter-30.45%
Sales0.45M P/S5.48 EPS this Y81.57% Inst Trans- Short Ratio0.11 Perf Half Y-53.79%
Book/sh-1.67 P/B- EPS next Y12.27% ROA-139.57% Short Interest0.09M Perf Year-82.93%
Cash/sh1.92 P/C0.88 EPS next 5Y- ROE-316.77% 52W Range1.30 - 13.20 Perf YTD-36.70%
Dividend Est.- P/FCF- EPS past 5Y32.13% ROI- 52W High-87.20% Beta0.60
Dividend TTM- Quick Ratio0.58 Sales past 5Y-20.00% Gross Margin94.43% 52W Low30.00% ATR (14)0.26
Dividend Ex-Date- Current Ratio0.58 EPS Y/Y TTM23.28% Oper. Margin-5749.22% RSI (14)40.41 Volatility7.94% 11.17%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin-4420.27% Recom1.00 Target Price11.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q67.58% Payout- Rel Volume0.03 Prev Close1.65
Sales Surprise- EPS Surprise52.16% Sales Q/Q- EarningsMay 14 AMC Avg Volume846.17K Price1.69
SMA20-18.50% SMA50-17.99% SMA200-55.06% Trades Volume26,199 Change2.42%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $17
Apr-27-20Resumed ROTH Capital Buy $24
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Jun-06-24 12:00PM
Jun-04-24 08:00AM
Jun-03-24 08:00AM
May-15-24 05:01AM
May-14-24 04:05PM
09:15AM Loading…
May-08-24 09:15AM
May-02-24 04:30PM
Apr-30-24 02:37PM
Apr-01-24 09:15AM
Mar-20-24 10:05AM
Mar-19-24 08:53PM
04:05PM Loading…
Mar-13-24 04:05PM
Mar-07-24 09:15AM
Mar-06-24 09:15AM
Feb-20-24 09:15AM
Jan-30-24 09:15AM
Jan-09-24 09:07AM
Jan-08-24 09:15AM
Jan-02-24 09:15AM
Dec-22-23 09:15AM
Dec-20-23 10:52AM
Dec-18-23 09:00AM
Dec-12-23 04:05PM
Nov-30-23 09:15AM
Nov-29-23 12:34PM
05:15PM Loading…
Nov-28-23 05:15PM
Nov-14-23 10:46AM
Nov-13-23 04:05PM
Nov-07-23 09:15AM
Aug-10-23 06:42AM
Aug-09-23 04:05PM
Aug-03-23 09:15AM
Jul-13-23 12:00PM
May-16-23 11:42AM
May-12-23 05:52AM
May-11-23 04:05PM
May-04-23 09:15AM
May-03-23 09:15AM
Mar-08-23 10:45PM
Mar-07-23 09:15AM
Mar-06-23 04:05PM
Feb-27-23 09:15AM
Jan-30-23 09:15AM
Jan-05-23 09:15AM
Dec-15-22 09:15AM
Nov-09-22 04:05PM
Nov-07-22 10:33AM
Nov-03-22 09:15AM
Oct-26-22 09:15AM
Oct-24-22 09:15AM
Oct-13-22 09:15AM
Sep-21-22 09:15AM
Aug-10-22 04:05PM
Aug-03-22 09:15AM
Jun-30-22 12:46PM
Jun-22-22 07:04AM
Jun-14-22 09:23AM
May-11-22 04:05PM
May-04-22 09:15AM
Apr-19-22 09:15AM
Apr-15-22 08:33AM
Apr-12-22 07:00AM
Mar-28-22 04:05PM
Mar-22-22 07:00AM
Mar-09-22 07:00AM
Feb-07-22 07:00AM
Jan-06-22 07:00AM
Dec-23-21 07:00AM
Dec-20-21 02:00AM
Dec-07-21 05:25AM
Nov-10-21 04:05PM
Nov-05-21 09:41AM
Oct-29-21 07:00AM
Oct-04-21 09:00AM
Sep-08-21 07:00AM
Aug-11-21 04:05PM
Aug-03-21 07:00AM
Jul-13-21 07:00AM
Jul-07-21 07:15AM
May-17-21 08:30PM
May-12-21 04:05PM
May-05-21 07:00AM
Mar-16-21 04:05PM
Mar-15-21 07:16AM
Mar-12-21 08:30AM
Mar-11-21 04:01PM
Feb-25-21 04:05PM
Feb-19-21 07:00AM
Feb-10-21 07:00AM
Feb-01-21 10:05PM
Jan-11-21 07:46AM
Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rombotis Spiro GeorgePresident and CEODec 21 '23Buy3.316,07020,12268,658Dec 26 04:05 PM
McBarron PaulSee RemarksDec 21 '23Buy3.311,8866,25233,378Dec 26 04:05 PM